Savara Pharmaceuticals, an inhalation drug development company, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the SAFE-BioPharma digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

 

Savara, which focuses on improving existing small molecule medicines through advanced formulation and delivery technologies across a number of therapeutic areas including asthma, cystic fibrosis and lung cancer, is incorporating the SAFE-BioPharma standard to improve its overall operating efficiencies.

 

“We are about to enter clinical trials and wanted a tool to help us eliminate paper from our systems, save time and become more efficient. For us, SAFE BioPharma is the logical choice,” said Chris Marich, vice president, business operations, Savara.

 

SAFE-BioPharma digital signatures are uniquely linked to the individual’s authenticated identity and are more secure and legally-binding than conventional electronic signatures. They are recognized by regulatory agencies throughout the U.S. and Europe.